Supranuclear OphthalmoplegiaSymptoms, Doctors, Treatments, Advances & More
Supranuclear Ophthalmoplegia Overview
Learn About Supranuclear Ophthalmoplegia
Supranuclear ophthalmoplegia is a condition that affects the movement of the eyes.
Progressive supranuclear palsy - supranuclear ophthalmoplegia; Encephalitis - supranuclear ophthalmoplegia; Olivopontocerebellar atrophy - supranuclear ophthalmoplegia; Amyotrophic lateral sclerosis - supranuclear ophthalmoplegia; Whipple disease - supranuclear ophthalmoplegia; Dementia - supranuclear ophthalmoplegia
This disorder occurs because the brain is sending and receiving faulty information through the nerves that control eye movement. The nerves themselves are healthy.
People who have this problem often have progressive supranuclear palsy (PSP). This is a neurologic disorder that affects the way the brain controls movement, including eye movement.
Other disorders that have been associated with supranuclear ophthalmoplegia include:
- Inflammation of the brain (encephalitis)
- A disease that causes areas deep in the brain, just above the spinal cord, to shrink (olivopontocerebellar atrophy)
- A condition that also causes a malabsorption disorder of the small intestine as well as other symptoms (Whipple disease)
People with supranuclear ophthalmoplegia are unable to move their eyes at will in all directions, especially looking upward.
Depending on what condition may be causing the supranuclear ophthalmoplegia, associated symptoms may include:
- Mild dementia
- Stiff and uncoordinated movements like those of Parkinson disease
- Symptoms of disorders associated with supranuclear ophthalmoplegia
Treatment depends on the cause and symptoms of the supranuclear ophthalmoplegia.
Memory And Aging Center
Adam Boxer is a Neurologist practicing medicine in San Francisco, California. Dr. Boxer is rated as an Elite provider by MediFind in the treatment of Supranuclear Ophthalmoplegia. He is also highly rated in 21 other conditions, according to our data. His clinical expertise encompasses Progressive Supranuclear Palsy, Progressive Supranuclear Palsy Atypical, Supranuclear Ophthalmoplegia, and Corticobasal Degeneration. Dr. Boxer is board certified in American Board Of Psychiatry/Neurology-Psychiatry, Neurology. Dr. Boxer is currently accepting new patients.
Matthias Brendel practices practicing medicine in Munich, Germany. Mr. Brendel is rated as an Elite expert by MediFind in the treatment of Supranuclear Ophthalmoplegia. He is also highly rated in 22 other conditions, according to our data. His clinical expertise encompasses Progressive Supranuclear Palsy, Progressive Supranuclear Palsy Atypical, Supranuclear Ophthalmoplegia, and Dementia.
UChicago Medicine Duchossois Center For Advanced Medicine - Hyde Park
Tao Xie is a Neurologist practicing medicine in Chicago, Illinois. Dr. Xie is rated as an Elite provider by MediFind in the treatment of Supranuclear Ophthalmoplegia. He is also highly rated in 19 other conditions, according to our data. His clinical expertise encompasses Progressive Supranuclear Palsy Atypical, Progressive Supranuclear Palsy, Supranuclear Ophthalmoplegia, Deep Brain Stimulation, and Gastrostomy. Dr. Xie is board certified in Neurology and Practicing Since2010. Dr. Xie is currently accepting new patients.
The outlook depends on the cause of the supranuclear ophthalmoplegia.
Summary: The Progressive Supranuclear Palsy Clinical Trial Platform (PTP) is a multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of PSP.
Summary: This Phase III study is intended to evaluate the efficacy and safety of NIO752 in participants with Progressive Supranuclear Palsy (PSP). Eligible participants will be randomized to receive either NIO752 or placebo followed by an open-label extension.
Published Date: May 04, 2026
Published By: Joseph V. Campellone, MD, Professor of Neurology, Cooper-Inspira Neuroscience, Cooper Medical School of Rowan University, Camden, NJ. Review provided by VeriMed Healthcare Network. Also reviewed by David C. Dugdale, MD, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team.
Jankovic J. Parkinson disease and other movement disorders. In: Jankovic J, Mazziotta JC, Pomeroy SL, Newman NJ, eds. Bradley and Daroff's Neurology in Clinical Practice. 8th ed. Philadelphia, PA: Elsevier; 2022:chap 96.
Lavin PJM, Donahue SP, Longmuir RA. Disorders of supranuclear control of ocular motility. In: Yanoff M, Duker JS, eds. Ophthalmology. 6th ed. Philadelphia, PA: Elsevier; 2023:chap 9.14.
Rucker JC, Lavin PJM. Neuro-ophthalmology: ocular motor system. In: Jankovic J, Mazziotta JC, Pomeroy SL, Newman NJ, eds. Bradley and Daroff's Neurology in Clinical Practice. 8th ed. Philadelphia, PA: Elsevier; 2022:chap 18.


